End-stage renal disease (ESRD) is the final stage of chronic kidney disease, where kidneys can no longer function effectively, requiring dialysis or a kidney transplant. It accounts for a significant portion of global kidney disease cases, affecting approximately 850 million people worldwide. There is a need for advanced therapies to treat ESRD, as current treatments, such as dialysis, focus on symptom management rather than addressing the root causes. Increasing emphasis on innovative therapeutics, including novel end-stage renal disease drug candidates and advanced biologics, is expected to drive substantial growth in the coming years, enhancing patient outcomes and quality of life.
Major companies involved in the end stage renal disease pipeline drugs market include AstraZeneca, Merck Sharp & Dohme LLC, and others.
Leading drugs currently in the pipeline include Sirolimus, DCR-PHXC, AZD4144, and others.
The rising global prevalence and increased investment in innovative therapeutics are driving the growth of the end-stage renal disease drug pipeline.
The End Stage Renal Disease Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into end stage renal disease therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for end stage renal disease. The end stage renal disease report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The end stage renal disease pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with end stage renal disease treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to end stage renal disease.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
End-stage renal disease (ESRD) is the final stage of chronic kidney disease, in which kidneys lose nearly all their function, leading to waste and fluid buildup. It typically occurs due to long-term conditions like diabetes, hypertension, or glomerulonephritis. Without proper treatment, ESRD can be life-threatening as the kidneys can no longer maintain essential bodily functions.
End-stage renal disease (ESRD) treatments focus on replacing lost kidney function. Options include dialysis—hemodialysis or peritoneal dialysis—to remove waste and excess fluid or kidney transplantation for a permanent solution. Managing underlying conditions and lifestyle changes are also crucial. Early diagnosis and treatment improve outcomes and quality of life.
End-stage renal disease (ESRD) affects over 2.6 million people globally, with rising incidence, particularly in Asia and the Americas. India reports 1,800 cases per million, with many requiring long-term renal replacement therapy. Hypertensive ESRD constitutes 25% of new cases in the USA, disproportionately impacting Black Americans, Asian Americans, and Alaska Natives.
This section of the report covers the analysis of end stage renal disease drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total end stage renal disease clinical trials.
The drug molecule categories covered under the end stage renal disease pipeline analysis include small molecules, biologics, peptides, gene therapies, and cell therapies. The end stage renal disease report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for end stage renal disease.
The EMR report for the end stage renal disease drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed end stage renal disease therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in end stage renal disease clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for end stage renal disease. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of end stage renal disease drug candidates.
Sirogen, sponsored by Vascular Therapies, is currently being evaluated in the Phase III ACCESS 2 trial to improve arteriovenous (AV) fistula outcomes for hemodialysis patients with kidney disease. This sirolimus-eluting collagen implant delivers sirolimus locally to enhance fistula maturation and reduce failure rates. The study’s primary endpoint is fistula maturation at six months, with results expected by Q2 2025.
DCR-PHXC, sponsored by Dicerna Pharmaceuticals, Inc., a Novo Nordisk company, is being evaluated in a Phase II open-label study. It is designed to assess its safety and efficacy in patients with Primary Hyperoxaluria Type 1 (PH1) and end-stage renal disease (ESRD), with or without dialysis. This investigational drug targets hepatic oxalate production, aiming to reduce oxalate accumulation and prevent further renal damage.
AZD4144 is an investigational drug developed by AstraZeneca, currently being evaluated in a Phase I study. It aims to assess its pharmacokinetics, safety, and tolerability in participants with severe renal impairment, including end-stage kidney disease (ESKD), compared to healthy individuals. This open-label, single-dose trial involves multiple cohorts, with findings expected to enhance future ESRD therapeutics and address critical treatment gaps.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The End Stage Renal Disease Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for end stage renal disease. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into end stage renal disease collaborations, regulatory environments, and potential growth opportunities.
Global Chronic Renal Failure Therapeutic Market Report
Renal Anemia Drug Pipeline Analysis
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share